HOME >> BIOLOGY >> NEWS
Unstable leukemia stem cells may predispose patients to drug resistance

The BCR-ABL gene in chronic myeloid leukemia stem cells has a tendency to quickly mutate, and this may help explain why patients are predisposed to resistance to drugs like imatinib that target that gene, according to a study in the May 2 Journal of the National Cancer Institute.

Treatment with imatinib causes clinical remissions in most patients with chronic myeloid leukemia, but relapses are common and the cancer can become resistant to the drug. The oncogene, BCR-ABL, is the cause of chronic myeloid leukemia. Researchers have hypothesized that the relapses are due to chronic myeloid leukemia stem cells with specific BCR-ABL gene mutations that make them resistant to the drug long before they are exposed to it.

Xiaoyan Jiang, M.D, Ph.D., and Connie Eaves, Ph.D., of the British Columbia Cancer Agency in Vancouver, and colleagues isolated chronic myeloid leukemia stem cells from patients and analyzed them to identify mutations in the BCR-ABL gene.

The stem cells were found to be genetically unstable and had a high frequency of mutations, even in the absence of imatinib. The researchers identified more than 70 BCR-ABL mutations in the stem cells and their immediate progeny, many of which would be expected to alter the BCR-ABL proteinthe target of imatinib. This could result in resistance to the drug.

Although this study was not designed to identify mutations that would contribute to disease progression, our results suggest that these would also be found. These considerations highlight the importance of gaining further understanding of the control of DNA replication and repair in the leukemic stem cells from patients with chronic phase [chronic myeloid leukemia] in future efforts to devise therapies with curative potential, the authors write.

In an accompanying editorial, Margret Rodrigues, Ph.D., and Martin Sattler, Ph.D., of the Dana Farber Cancer Institute in Boston, discuss the possible causes of gen
'"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
1-May-2007


Page: 1 2

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Scientists gain important insights into acute promyelocytic leukemia
3. Modular leukemia drug shows promise in early testing
4. Researchers discover inherited mutation for leukemia
5. Inherited genes linked to toxicity of leukemia therapy
6. Tree rings show elevated tungsten coincides with Nevada leukemia cluster
7. Cancer scientists create human leukemia process to map how disease begins, progresses
8. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
9. Knocking out survival protein could aid leukemia treatment
10. Massey researchers induce cell death in leukemia
11. Progress toward a targeted therapy for a specific form of leukemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/30/2019)... , ... September 30, 2019 , ... ... focused on molecular manufacturing and other transformative technologies, announced the winners for the ... Experiment and the other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem ... for studying the development and diseases of the human heart, there is an increasing ... progeny heart muscle cells to be clearly and easily recorded. A study released today ...
(Date:9/30/2019)... Calif. (PRWEB) , ... September ... ... a leading think tank, research, and public interest organization focused on molecular ... Distinguished Student Prize. , The Award recognizes the College graduate or undergraduate ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... October 01, 2019 , ... Today ... itself, announced the midway point of its randomized research trial for individuals with ... to measure the efficacy of a non-invasive technology which compares tones delivered to ...
(Date:10/3/2019)... ... October 02, 2019 , ... Murrieta Genomics , the launch ... venture capital companies in Silicon Valley at a special Life Science showcase event ... be held at the JJ Lake Business Center located at 340 E. Middlefield Road ...
(Date:10/3/2019)... ... ... Yesterday, at the 2019 meeting of Outsourcing in Clinical Trials New England ... Ph.D., discussed important design factors that currently limit the success of early stage stem ... clinical trials, in his talk Dr. Sherley focused on the highly problematic ...
(Date:9/24/2019)... ... September 24, 2019 , ... Drug resistance has been declared as one ... with MRSA becoming one of the most serious concerns. Hong Kong cannot be spared ... community-associated MRSA (CA-MRSA), or a seven-fold of the figure in 2007 – the year ...
Breaking Biology Technology:
Cached News: